Overview

The purpose of this transgene assay testing service is to evaluate the tumor samples for transgene levels in patients who received a Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying secondary malignancy.

Eligibility

Inclusion Criteria:

        • Participant has received a Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell
        Therapy (GMCT) and has been diagnosed with a qualifying secondary malignancy suspected of
        T-cell origin.
        OR • Participant has received a Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell
        Therapy (GMCT) and has been diagnosed with a secondary malignancy qualifying for further
        investigation.
        AND
        • Participant is not actively participating in a clinical trial where information and
        sample collection is being conducted under that clinical trial.
        Exclusion Criteria:
          -  Participant is actively participating in a clinical trial where information and sample
             collection is being conducted under that clinical trial.
          -  Participant has not received a Bristol-Myers Squibb (BMS) manufactured Gene Modified
             Cell Therapy (GMCT) or has not been diagnosed with a qualifying secondary malignancy.